To further explore the impact of aT-sEV PD-1/CD80 on the efficacy of anti-PD-1 immunotherapy, we utilised mice bearing MC38 tumours as an appropriate cancer model due to their ability to elicit a moderate immune response35–37. This evidence concerns the gene CD80 and cancer.